Core therapeutic areas

Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs

Current business is led by core therapeutic areas Sales 9M 2014 31% Infection, Neuroscience, Gastrointestinal 12% 19% 38% Oncology RIA CVMD 69% Note: RIA: Respiratory, Inflammation & Autoimmunity CVMD: Cardiovascular & Metabolic Disease 2 Core therapeutic areas

Broad geographical presence; Emerging Markets strength US 39% of sales Europe 25% of sales China 9% of sales Japan 9% of sales Emerging Markets (ex-china) 13% of sales ROW Established (ex-japan) 5% of sales Note: Sales 9M 2014 3 Core therapeutic areas

Respiratory, Inflammation & Autoimmunity (RIA) Cardiovascular & Metabolic Disease (CVMD) Oncology 4 Core therapeutic areas

Respiratory: Unique position in bringing leading medicines to patients Large & small molecules with compelling science Diversity in formulation to enable unique combinations Leading devices & choice for patients 5 Core therapeutic areas

Respiratory: Unmet need remains in asthma and COPD Asthma COPD Active patients, millions, 2014 GOLD-defined patients, millions, 2014 GINA step GOLD stage 1.8m severe, 4-5 3-4 1.6m severe, 60 inadequately inadequately 1-3 controlled despite 1-2 controlled despite compliance compliance 44 44 38 11 24 19 9 Asthma prevalence Diagnosed Treated Poor control COPD prevalence Diagnosed Treated Poor control Note: G7 markets = US, France, Germany, Italy, Spain, UK, Japan Source: Decision Resources; Adelphi DSP 2012; other 6 Core therapeutic areas

COPD: Affects ~300 million* people; highest prevalence in developing countries Male smoking prevalence trends by region (2011) Lifetime male smoking prevalence: 60% and above 50-59.9% 40-49.9% 30-39.9% 20-29.9% Below 20% No Data * Global estimate of diagnosed and undiagnosed patients Source: Decision Resources; Adelphi DSP 2012; AZ internal analysis of G8 and ROW uplift 7 Core therapeutic areas

Symbicort & Pulmicort: Growth by EM / Japan, new indications & new devices Emerging Markets / Japan Market growth driven by: Improving diagnosis Improving access to drug treatment Environmental factors and smoking New indications COPD label updates COPD exacerbations US Asthma SMART labelling Mild asthma: Ex-US as needed Symbicort / PT001 open triple New devices Intelligent device EU Symbicort pmdi EU Symbicort BAI Symbicort Pearl co-suspension Pulmicort nebuliser expansion and Pearl co-formulation Source: UN Population Database, IMS Midas, other forecasts 8 Core therapeutic areas

Symbicort: Resilience driven by devices Negative impact of switch is well documented * Successful treatment Partially successful treatment Unsuccessful treatment Change in SABA dose Device has a very strong impact on prescription decision **,*** 57-69% of healthcare providers rate device as having very significant impact Proportion of patients (%) 100 80 60 40 20 0 19.7 29.6 50.7 Switch (n=824) 34.3 27.8 37.9 Non-switch (n=824) 0.40 0.20 0.20 0.10 0-0.10-0.20 Mean 95% CI change in SABA daily dose 0% 0% 2% 4% 6% 9% 23% 32% 13% 11% 1 2 3 4 5 6 7 8 9 10 Healthcare providers switch device typically in <10% of consultations Thomas M, Price D, Chrystyn H, et al. Inhaled corticosteroids for asthma: Impact of practice level device switching on asthma control. BMC Pulm Med 2009; 9: 1. ** Qual MR ; 70 HCP and 149 Patient Depth Interviews; Chn, Jpn, Ge, Sp & USA; Q1 2014 Fast Forward Research *** Quant MR; 882 Physician On-line survey; Chn Jpn, Ge, Sp & USA; Q1 2014 IPSOS 9 Core therapeutic areas

Inflammation & Autoimmunity: Strategy Progressing pipeline of first-in-class, best-in-class medicines Rheumatology Dermatology Gastrointestinal Gout Lupus Rheumatoid arthritis Co-development with Amgen Psoriasis and psoriatic arthritis Co-development with Amgen Crohn s disease Ulcerative colitis 10 Core therapeutic areas

Inflammation & Autoimmunity: Significant growth potential Global markets for rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus, ulcerative colitis, Crohn s disease and gout $bn 60 50 $50bn 40 30 $30bn 20 10 0 Now RA PsO&PsA Lupus UC&CD Gout Future Source: IMS, biologic and novel oral brand sales by indication; Decision Resources 11 Core therapeutic areas

Respiratory, Inflammation & Autoimmunity (RIA) Cardiovascular & Metabolic Disease (CVMD) Oncology 12 Core therapeutic areas

Diabetes: Significant T2D disease burden exists globally 380 million people with diabetes worldwide Anticipated to grow to 590 million by 2035 55% increase in prevalence Lower T2D mortality Significant increase in Emerging Markets Source: International Diabetes Foundation Atlas 6 edition, International Diabetes federation 2013 13 Core therapeutic areas

Diabetes: Non-insulin diabetes market to continue endemic growth Expected revenues for insulin and other diabetes products $bn 47.3 5.5 6.4 27.8 4.2 3.2 8.5 11.8 2013 8.8 9.8 16.7 2022 Other SGLT-2 GLP-1 DPP-4 Insulin Source: Decision Resources (2014), Type 2 Diabetes Therapy 14 Core therapeutic areas

Diabetes: Innovative portfolio spanning all non-insulin classes DPP-4 Orals SGLT-2 FDC SGLT-2 / DPP-4 saxa-dapa Injectables GLP-1 Amylin analogue 15 Core therapeutic areas

Brilinta: Strengthening momentum Ticagrelor also increases adenosine, augments vasodilation, coronary flow, inhibition of platelet function, and dyspnoea ATLANTIC Ambulance as effective as Cath-Lab Europe label change ESC, ATLANTIC & APOLLO PEGASUS headline Q3 2014 Q4 2014 DOJ closure New AHA guidelines AHA APOLLO: ~1 in 5 patients will suffer an MI, stroke or CV death within the first year after an MI Ticagrelor >clopidogrel for ischaemic guided and early invasive NSTE-ACS patients 16 Core therapeutic areas

Respiratory, Inflammation & Autoimmunity (RIA) Cardiovascular & Metabolic Disease (CVMD) Oncology 17 Core therapeutic areas

Oncology: Cancer incidence a global healthcare challenge Breast cancer treated patients Over 8.2m adults die each year from cancer Over 13m people are predicted to die from cancer in 2030 800,000 600,000 400,000 200,000 0 2015 2025 US EU5 JP CN 1,200,000 1,000,000 800,000 600,000 400,000 200,000 0 NSCLC 1L treated patients 2015 2025 US EU5 JP CN 100,000 80,000 60,000 40,000 20,000 Ovarian cancer 1L treated patients 0 2015 2025 US EU5 JP CN Source: NSCLC: Kantar Health Patient Metrics (US, UK, Spain, Italy), AZ internal sources (France, Germany, Japan and China) Breast: Kantar Health Patient Metrics (US, EU5, Japan), AZ internal sources (China) Ovarian: Kantar Health Patient Metrics (US, EU5, Japan); Decision Resources (China, Urban) Global Incidence and Mortality Numbers: Globocan 2012 (IARC) Projection. Population forecasts taken from UN, World Populations Prospects (2012 revision) Forecast market size Decision Resources Pharmaview 18 Core therapeutic areas

Increasing importance of specialty care Primary care vs specialty care sales over time Future Now Primary Care Specialty Care 19 Core therapeutic areas

Confidence in strategy Core therapeutic areas platform for growth Broad geographical presence with strong EMs Aligned with pipeline Pipeline driving a balance of primary and specialty care 20 Core therapeutic areas

Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs